<code id='46EC1F76D3'></code><style id='46EC1F76D3'></style>
    • <acronym id='46EC1F76D3'></acronym>
      <center id='46EC1F76D3'><center id='46EC1F76D3'><tfoot id='46EC1F76D3'></tfoot></center><abbr id='46EC1F76D3'><dir id='46EC1F76D3'><tfoot id='46EC1F76D3'></tfoot><noframes id='46EC1F76D3'>

    • <optgroup id='46EC1F76D3'><strike id='46EC1F76D3'><sup id='46EC1F76D3'></sup></strike><code id='46EC1F76D3'></code></optgroup>
        1. <b id='46EC1F76D3'><label id='46EC1F76D3'><select id='46EC1F76D3'><dt id='46EC1F76D3'><span id='46EC1F76D3'></span></dt></select></label></b><u id='46EC1F76D3'></u>
          <i id='46EC1F76D3'><strike id='46EC1F76D3'><tt id='46EC1F76D3'><pre id='46EC1F76D3'></pre></tt></strike></i>

          fashion

          fashion

          author:explore    Page View:9
          glum Benjamin — health insurance coverage from STAT
          Adobe

          Startup insurers Oscar Health, Bright Health, and Clover Health have hemorrhaged money since going public within the past two years. All three used their stage time at the J.P. Morgan Healthcare Conference to make the case that their drastic decisions — like fully exiting some insurance markets — will deliver the profitability investors are demanding.

          “Insurance company profitability is the number one goal,” Oscar CEO Mario Schlosser said in an interview with STAT in San Francisco.

          advertisement

          “We are actually absolutely focused on profitability right now,” Clover CEO Andrew Toy said during his presentation on Wednesday.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          New details revealed about Purdue's marketing of OxyContin
          New details revealed about Purdue's marketing of OxyContin

          MassachusettsAttorneyGeneralMauraHealeyJessicaRinaldi/TheBostonGlobeWhenPurduePharmastartedsellingit

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          JPM 2024: Verve Therapeutics looks to mainstream genome editing

          VerveTherapeuticsCEOSekarKathiresanVerveSANFRANCISCO—Thepromiseofgenomeeditinghasgivenrisetopotentia